A Motion-Sickness Pill Cut Wegovy Vomiting by 27%, Half Its Early Result

One injection pen, one 1 mg dose of semaglutide, and no warm-up. On the normal Wegovy schedule nobody reaches 1 mg until week nine, after eight weeks on smaller doses, because the label says stomach side effects cluster during the climb. In the trial Vanda Pharmaceuticals reported on Tuesday morning, people skipped the climb on purpose, and more than half of those on a dummy pill threw up. We read the company’s release line by line, the trial’s registry record, the earlier study it was built on and the Wegovy label, to answer the question GLP-1 users are now typing: does the motion-sickness pill tradipitant actually stop the vomiting?

The short version: yes, partly. The pill cut vomiting by about a quarter in the big trial, which is real and statistically solid, and about half the cut the smaller first study suggested. Below are the numbers, why a seasickness drug might work on a weight-loss shot, what the harsh test design means for everyday users, and what is still unknown.

The result: In Study 3601, 43.0% vomited on tradipitant against 58.5% on placebo

According to Vanda’s October 27, 2026 release, Study 3601 randomly assigned people to tradipitant, sold as NEREUS, or to a placebo, then gave everyone a single 1 mg dose of semaglutide, the drug in Wegovy and Ozempic, without the usual gradual increase. Vomiting, the main measure, happened in 61 of 142 people on tradipitant (43.0%) and 96 of 164 on placebo (58.5%). Vanda reports that as a 27% relative reduction, with a p-value of 0.006, which means a result this large would be unlikely if the pill did nothing.

The key secondary measure, vomiting together with severe nausea, fell from 50.6% on placebo to 33.1% on tradipitant in the Vanda release, a 35% relative cut (p=0.002). The company also reports two larger effects at the hard end: vomiting on several days fell from 15.9% to 6.3%, and more than ten vomiting episodes fell from 14.6% to 2.8%. Vanda labels both as post hoc analyses presented as supportive evidence, which means they were run after the trial ended rather than set as goals in advance, so they point a direction rather than prove one. By our arithmetic, 14.6% of 164 is about 24 people and 2.8% of 142 is about 4.

The registry record, NCT07446439, fills in what the release leaves out. Study 3601 is the trial Vanda calls Thetis: a Phase 3 study in healthy adults with a body mass index from 25 to under 40 and no type 1 or type 2 diabetes, with tradipitant or placebo taken twice a day for about two weeks. Vanda says “almost all vomiting episodes in either group occurred by Day 2.” The release reports the drug was generally well tolerated, with a safety profile consistent with previous studies.

The comparison: The first study promised a 50% cut. The bigger trial delivered 27%.

Vanda’s first look at this question was Study 2601, announced November 17, 2025: 116 people took tradipitant 85 mg twice daily, starting a week before a single 1 mg Wegovy injection. Vomiting fell from 58.6% on placebo to 29.3% on tradipitant, a 50% relative reduction. The placebo groups in the two studies vomited at almost the same rate, 58.6% and 58.5%, so the test was equally hard both times. What changed was the drug arm: 29.3% in the small study, 43.0% in the large one.

Our reading: this is the common path from a small study to a bigger one, where an early effect shrinks once more people and more sites are added. A 27% cut still counts. By our arithmetic, the 15.5-point gap means roughly one fewer person vomiting for every six or seven people who take the pill under these test conditions. Vanda also cites a pooled analysis of both studies linking higher drug levels to better protection; the release does not give its numbers, so we cannot check it.

The mechanism: Why a seasickness pill might work on a weight-loss shot

GLP-1 drugs make people feel sick mostly through the brain, not only the stomach. A 2022 review in the British Journal of Pharmacology (PubMed 34363224) concludes that the appetite-cutting and vomiting effects of GLP-1 receptor agonists are caused by switching on GLP-1 receptors in the central nervous system.

Tradipitant works one step further down that line. As a 2026 drug profile in Drugs (PubMed 41945307) explains, it blocks the NK-1 receptor, the docking site for substance P, a chemical messenger whose release in the brain leads to nausea and vomiting. That is the same pathway behind motion sickness, which is why the FDA approved NEREUS in December 2025 to prevent vomiting caused by motion. Our reading: the GLP-1 trials test whether that shared final step can be blocked without touching what the weight-loss drug does elsewhere. Vanda has not reported weight or appetite results from Study 3601.

The everyday version: Most Wegovy users never face a test this harsh

The trial was built to make people sick, so it could measure prevention. Real-world use is gentler. The Wegovy prescribing information starts at 0.25 mg a week and raises the dose every four weeks, reaching 1 mg only in weeks 9 to 12. On that schedule, in the adult weight-loss trials behind the label, 24% of people on the full 2.4 mg dose reported vomiting against 6% on placebo, and 44% reported nausea against 16%. The label says these reactions were most often reported during the dose climb, and that 1.2% of people stopped the drug because of vomiting and 1.8% because of nausea.

So the 58.5% placebo figure in Study 3601 is not what an ordinary user should expect; it is the cost of a deliberate shortcut. Our reading: the open question for an approval is whether tradipitant helps on the normal schedule, and in the people most likely to need it, such as those who stall on a dose increase. Study 3601 enrolled healthy volunteers without diabetes, so it does not answer that yet. For more on what these drugs do to digestion day to day, see our Ozempic and your gut explainer and our read on fiber on a GLP-1.

What happens next: Vanda plans to ask the FDA to add GLP-1 vomiting to the label

Vanda says in its release that it will discuss the results with the FDA and plans to file a supplemental New Drug Application, the request to add a new use to an approved drug. NEREUS is approved today only to prevent vomiting caused by motion. Any use for GLP-1 side effects would be off-label until the FDA decides, and the release gives no timeline for a filing or a decision. The Study 3601 results have not been published in a peer-reviewed journal.

How we checked this: Sources and method

We read Vanda’s October 27, 2026 release on PR Newswire and its November 17, 2025 release on Study 2601, the ClinicalTrials.gov record NCT07446439, the current Wegovy prescribing information on DailyMed (published June 30, 2026), and two PubMed papers, 41945307 and 34363224, each matched by title. All Study 3601 figures are company-reported and not yet peer reviewed. The absolute differences, the one-in-six-or-seven figure and the head counts are our arithmetic from the published percentages. This article is educational, describes what the cited sources say, and is not medical advice; anyone with ongoing vomiting on a GLP-1 drug should talk to their prescriber.